Peripheral stem cell mobilization and engraftment in patients over age 60

Bone Marrow Transplantation

Volumn 20, Issue 1, 1997, Pages 1-3

  Guba, S C ^a   Vesole, D H ^a   Jagannath, S ^a   Bracy, D ^a   Barlogie, B ^a   Tricot, G ^a,b  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^b NONE   (United States)

Author keywords

Autotransplantation; Geriatrics; Peripheral stem cell

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; CLINICAL TRIAL; ELDERLY CARE; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; NEUTROPHIL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; THROMBOCYTE COUNT;

EID: 0030758629     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700833     Document Type: Article

References (14)

1. Yancik R, Ries LA. Cancer in older persons magnitude of the problem. How do we apply what we know? Cancer Suppl 1994; 74: 1995-2003.
2. Miller BA, Ries LAG, Hankey BF et al (eds). SEER Cancer Statistics Review: 1973-1990. National Cancer Institute: Bethesda 1993, NIH Report No. 93-2789.
3. Yellen SB, Cella DF, Leslie WT. Age and clinical decision making in oncology patients. J Natl Cancer Inst 1994; 86: 1766-1770.
4. Barlogie B, Epstein J, Selvanayagam P, Alexanian R. Plasma cell myeloma - new biological insights and advances and advances in therapy. Blood 1989; 73: 865-879.
5. Blade J, Lopez-Guillermo A, Bosch F et al. Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. Br J Haematol 1994; 88: 117-121.
6. Attal M, Harousseau JL, Stoppa AM et al. Prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New Engl J Med 1996; 335: 91-97.
7. Barlogie B, Jagannath S, Vesole D et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789-793.
8. Jagannath S, Vesole D, Glenn L et al. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 1992; 80: 1666-1672.
9. Vesole D, Tricot G, Jagannath S et al. Autotransplants in multiple myeloma: what have we learned? Blood 1996; 88: 838-847.
10. Tricot G, Jagannath S, Vesole D et al. Periphal blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-596.
11. Alexanian R, Balcerzak S, Bonnet JD et al. Prognostic factors in multiple myeloma. Cancer 1975; 36: 1192-1202.
12. 2 microglobulin in myeloma: a Southwest Oncology Group study. Blood 1990; 75: 823-830.
13. Levine EG, Bloomfield CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 1992; 19: 47-84.
14. Govindarajan R, Jagannath S, Flick JT et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol 1996; 95: 349-353.